SOP for Applying Stability Testing Guidelines for New Drug Submissions to EMA

Guidelines for Stability Testing of New Drug Submissions as per EMA Guidelines

1) Purpose

The purpose of this Standard Operating Procedure (SOP) is to provide guidelines for conducting stability testing for new drug submissions in accordance with the European Medicines Agency (EMA) guidelines. This SOP ensures that stability data supports the quality, safety, and efficacy of new drug products throughout their shelf life.

2) Scope

This SOP applies to all personnel involved in the design, execution, and documentation of stability studies for new drug submissions intended for the European market.

3) Responsibilities

Stability Testing Team: Responsible for conducting stability studies and documenting results in compliance with EMA guidelines.

Quality Assurance (QA) Team: Responsible for reviewing and approving stability study protocols and reports.

Regulatory Affairs Team: Responsible for ensuring that stability studies meet EMA regulatory expectations.

4) Procedure

4.1 Preparation for Stability Testing

4.1.1 Obtain and review the latest EMA guidelines

for stability testing of new drug submissions.

4.1.2 Develop a stability protocol specific to new drug products, including study design, testing schedule, storage conditions, and testing parameters as per EMA guidelines.

4.2 Selection of Batches and Samples

4.2.1 Select representative batches of the new drug product, typically three primary batches manufactured using the proposed production process.

4.2.2 Prepare sufficient samples to cover the entire study duration, considering the number of time points and tests to be conducted.

4.3 Defining Storage Conditions and Time Points

4.3.1 Define the storage conditions according to EMA guidelines, typically including:

Long-term stability: 25°C ± 2°C/60% RH ± 5% RH
Accelerated stability: 40°C ± 2°C/75% RH ± 5% RH

4.3.2 Establish the time points for sampling, such as 0, 3, 6, 9, 12, 18, and 24 months for long-term studies, and additional time points for accelerated studies.

4.4 Conducting Stability Tests

4.4.1 Store samples under the defined conditions, monitoring temperature and humidity to ensure compliance with the set parameters.

4.4.2 At each specified time point, remove samples and conduct stability-indicating tests, including physical, chemical, microbiological, and functional tests, as applicable.

4.4.3 Record all results meticulously in stability data sheets, ensuring accuracy and traceability of data.

5) Abbreviations, if any

EMA: European Medicines Agency
QA: Quality Assurance
RH: Relative Humidity

6) Documents, if any

Stability protocol, stability data sheets, stability testing records, stability report, submission package to EMA.

7) Reference, if any

EMA Guidelines on Stability Testing of New Drug Substances and Products.

8) SOP Version

Version 1.0